Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ambien CR Approval Includes Sleep Maintenance, Long-Term Use

Executive Summary

The approval of Sanofi-Aventis' Ambien CR (zolpidem extended-release) includes claims for sleep maintenance and long-term use that will allow the insomnia medication to compete against newer agents

You may also be interested in...



Ambien CR Generics Need Extra Bioequivalence Tests, Sanofi Argues To FDA

Sanofi-Aventis is requesting that FDA require additional bioequivalence tests for generic versions of its insomnia product Ambien CR (zolpidem extended-release)

Ambien CR Generics Need Extra Bioequivalence Tests, Sanofi Argues To FDA

Sanofi-Aventis is requesting that FDA require additional bioequivalence tests for generic versions of its insomnia product Ambien CR (zolpidem extended-release)

Ambien Class Action Suit May Serve As Wake-Up Call For Competitors

A civil class action lawsuit in Manhattan federal court alleging that Sanofi-Aventis failed to adequately warn patients of the risk of sleep walking and sleep eating with Ambien (zolpidem) could open the door for other agents in the highly competitive sleep category

Related Content

Topics

UsernamePublicRestriction

Register

PS046294

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel